COMMUNIQUÉS West-GlobeNewswire

Wounded Warriors Family Support Donates 2025 Ford F-150 Truck to Retired Marines Veteran
16/10/2025
KING OF PRUSSIA, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- A deserving veteran received the life-changing gift of mobility after a considerable donation Tuesday at Topgolf King of Prussia . Wounded Warriors Family Support [...]
Celebrating 50 Years of Katena: From One Woman’s Vision to a Global Legacy in Ophthalmology
16/10/2025
Honoring five decades of precision, partnership, and innovation that continue to shape the future of eye care PARSIPPANY, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Corza Medical, a global medical technology company, is [...]
EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter, best quarterly performance ever for the Group
16/10/2025
Revenue up 11.7% in the third quarter Best quarterly performance ever for the Group Group’s revenue +11.7% in the third quarter at constant exchange rates 1 , +8.8% in the nine months Wearables major boost, enlarging [...]
EssilorLuxottica: Chiffre d'affaires T3/9M 2025 - Chiffre d'affaires en hausse de 11,7 % au T3, meilleure performance trimestrielle du Groupe depuis sa création
16/10/2025
Chiffre d'affaires en hausse de 11,7 % au T3 Meilleure performance trimestrielle du Groupe depuis sa création Chiffre d'affaires T3 du Groupe à +11,7 % à taux de change constants 1 , +8,8 % sur les neuf premiers mois [...]
Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
16/10/2025
Ghent, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 16 [...]
VIRBAC Announces Third Quarter 2025 Sales
16/10/2025
Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scope Upgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at constant rates and [...]
VIRBAC annonce son chiffre d'affaires pour le troisième trimestre 2025
16/10/2025
Croissance soutenue du chiffre d’affaires à fin septembre de +7,8% à taux de change et périmètre constants Relèvement des objectifs financiers annuels de chiffre d’affaires Croissance du chiffre d'affaires attendue [...]
Channel Medsystems Strengthens Commercial Leadership Team with Appointments of Tara Murphy as Vice President of Marketing and Paul Russo as Vice President of Sales
16/10/2025
BERKELEY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointments of Tara Murphy as [...]
HCW Biologics to Participate in the 2025 Maxim Growth Summit
16/10/2025
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies [...]
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
16/10/2025
Company poster presentations will debut research data of three lead drug candidates constructed with Company’s novel TRBC platform technology MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” [...]
Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit
16/10/2025
THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
16/10/2025
Live webcast presentation on Tuesday, October 21st at 11:35 AM ET SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology [...]
CJ Biomaterials Introduces New PHACT™ PHA Masterbatch for Safer, Stronger, Softer, Home Compostable Spunbond Nonwovens and Staple Fiber
16/10/2025
Innovative solution that is ideal for wipes, diapers, hygiene, and beauty applications, offering enhanced performance and sustainability WOBURN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- CJ Biomaterials, Inc , a division [...]
Belite Bio to Participate in the 2025 Maxim Growth Summit
16/10/2025
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal [...]
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
16/10/2025
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc [...]
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
16/10/2025
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it [...]
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
16/10/2025
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher [...]
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
16/10/2025
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with [...]
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
16/10/2025
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated [...]

Pages